Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (1)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The selected severe-impairment ceiling is stated for kidney-transplant recipients. Mycophenolic-acid products have separate formulations and evidence.
Before applying: Preserve transplant organ, formulation and monitoring context; do not declare all mycophenolate products interchangeable.
Also check: MYHIBBIN: kidney-transplant dose ceiling is not every transplant setting
Rxlist source
GlobalRPh RX List - MYHIBBIN
Product / population
Mycophenolate mofetil - MYHIBBIN oral suspension; selected renal source sections only, not a complete prescribing monograph.
Renal measure
GFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
The source specifies GFR with indexed units, not a validated estimating equation; do not relabel as Cockcroft-Gault.
Renal dosing, restrictions and evidence limits
For kidney transplant recipients with severe chronic graft impairment (GFR <25 mL/min/1.73 m2), the source does not require a routine reduction but says to avoid doses above 1 g twice daily. Delayed graft function does not require an adjustment; carefully monitor. Severe renal impairment in heart or liver recipients lacks data, and use requires a benefit-risk assessment. This kidney-transplant ceiling is not a universal rule for every transplant organ or mycophenolate product.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-08. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
population scope
MYHIBBIN: kidney-transplant dose ceiling is not every transplant setting
The selected severe-impairment ceiling is stated for kidney-transplant recipients. Mycophenolic-acid products have separate formulations and evidence.
How to use this: Preserve transplant organ, formulation and monitoring context; do not declare all mycophenolate products interchangeable.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - MYHIBBIN
Mycophenolate mofetil - MYHIBBIN oral suspension; selected renal source sections only, not a complete prescribing monograph.
Method: GFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Mycophenolate mofetil - MYHIBBIN oral suspension; selected renal source sections only, not a complete prescribing monograph.
Renal method: GFR, mL/min/1.73 m2. Preserve the body-surface-area denominator. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For kidney transplant recipients with severe chronic graft impairment (GFR <25 mL/min/1.73 m2), the source does not require a routine reduction but says to avoid doses above 1 g twice daily. Delayed graft function does not require an adjustment; carefully monitor. Severe renal impairment in heart or liver recipients lacks data, and use requires a benefit-risk assessment. This kidney-transplant ceiling is not a universal rule for every transplant organ or mycophenolate product.
RDM47-rxlist-mycophenolate-mofetil-myhibbin-f979dc7124-C1 · Source locator: Dosage modifications and renal impairment; renal transplant, heart and liver populations.
Source-specific limits
The source specifies GFR with indexed units, not a validated estimating equation; do not relabel as Cockcroft-Gault.
Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.